Escherichia coli Infections – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Escherichia coli Infections – Pipeline Review, H2 2016’, provides an overview of the Escherichia coli Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Escherichia coli Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Escherichia coli Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Escherichia coli Infections

The report reviews pipeline therapeutics for Escherichia coli Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Escherichia coli Infections therapeutics and enlists all their major and minor projects

The report assesses Escherichia coli Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Escherichia coli Infections

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Escherichia coli Infections

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Escherichia coli Infections pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Adenium Biotech ApS

Arsanis, Inc.

AstraZeneca Plc

AvidBiotics Corp

Cellceutix Corp

Debiopharm International SA

Emergent BioSolutions Inc

F. Hoffmann-La Roche Ltd

GangaGen Inc

Hsiri Therapeutics LLC

Johnson & Johnson

Melinta Therapeutics Inc

Merck & Co Inc

Microbiotix Inc

Nabriva Therapeutics AG

Navigen Pharmaceuticals, Inc.

Nosopharm SAS

Novabiotics Ltd

Omnia Molecular Ltd

Paratek Pharmaceuticals Inc

Pherecydes Pharma SA

Phico Therapeutics Ltd

Procarta Biosystems Limited

Sealife PHARMA GMBH

Sequoia Sciences Inc

Soligenix Inc

Syntiron LLC

Tetraphase Pharmaceuticals Inc

Varinel Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Escherichia coli Infections Overview 9

Therapeutics Development 10

Pipeline Products for Escherichia coli Infections - Overview 10

Pipeline Products for Escherichia coli Infections - Comparative Analysis 11

Escherichia coli Infections - Therapeutics under Development by Companies 12

Escherichia coli Infections - Therapeutics under Investigation by Universities/Institutes 14

Escherichia coli Infections - Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Escherichia coli Infections - Products under Development by Companies 18

Escherichia coli Infections - Products under Investigation by Universities/Institutes 21

Escherichia coli Infections - Companies Involved in Therapeutics Development 22

Adenium Biotech ApS 22

Arsanis, Inc. 23

AstraZeneca Plc 24

AvidBiotics Corp 25

Cellceutix Corp 26

Debiopharm International SA 27

Emergent BioSolutions Inc 28

F. Hoffmann-La Roche Ltd 29

GangaGen Inc 30

Hsiri Therapeutics LLC 31

Johnson & Johnson 32

Melinta Therapeutics Inc 33

Merck & Co Inc 34

Microbiotix Inc 35

Nabriva Therapeutics AG 36

Navigen Pharmaceuticals, Inc. 37

Nosopharm SAS 38

Novabiotics Ltd 39

Omnia Molecular Ltd 40

Paratek Pharmaceuticals Inc 41

Pherecydes Pharma SA 42

Phico Therapeutics Ltd 43

Procarta Biosystems Limited 44

Sealife PHARMA GMBH 45

Sequoia Sciences Inc 46

Soligenix Inc 47

Syntiron LLC 48

Tetraphase Pharmaceuticals Inc 49

Varinel Inc 50

Escherichia coli Infections - Therapeutics Assessment 51

Assessment by Monotherapy Products 51

Assessment by Target 52

Assessment by Mechanism of Action 54

Assessment by Route of Administration 56

Assessment by Molecule Type 58

Drug Profiles 60

A-3APO - Drug Profile 60

AA-139 - Drug Profile 61

AM-8722 - Drug Profile 62

ASN-4 - Drug Profile 63

AvR2-V10 - Drug Profile 64

BC-7634 - Drug Profile 66

BC-9074 - Drug Profile 67

BC-9529 - Drug Profile 68

BC-9563 - Drug Profile 69

BIZ-20131 - Drug Profile 70

BIZ-20132 - Drug Profile 71

BIZ-20133 - Drug Profile 72

CA-824 - Drug Profile 73

CC-1807 - Drug Profile 74

Debio-1454 - Drug Profile 75

Drugs for Bacterial Infections - Drug Profile 76

dusquetide - Drug Profile 77

Escherichia coli (whole cell) vaccine - Drug Profile 82

Escherichia coli vaccine - Drug Profile 83

Escherichia coli vaccine - Drug Profile 84

ETEC [strain B7A] vaccine - Drug Profile 85

ETEC vaccine - Drug Profile 86

EV-035 - Drug Profile 87

GN-4474 - Drug Profile 89

GNEG SNARE - Drug Profile 90

HT-07 - Drug Profile 91

INX-201 - Drug Profile 92

JNJ-63871860 - Drug Profile 93

MBX-2319 - Drug Profile 95

MDN-0057 - Drug Profile 96

mirandamycin - Drug Profile 98

NBTI-5463 - Drug Profile 99

NOSO-95179 - Drug Profile 100

NP-432 - Drug Profile 101

omadacycline tosylate - Drug Profile 102

Onc-72 - Drug Profile 108

P-100031 - Drug Profile 109

Peptides for Infectious Diseases - Drug Profile 110

PMX-100 - Drug Profile 111

PMX-1091 - Drug Profile 112

PMX-1142 - Drug Profile 113

PMX-1241 - Drug Profile 114

PMX-1278 - Drug Profile 115

PMX-1363 - Drug Profile 116

PMX-1405 - Drug Profile 117

PMX-223 - Drug Profile 118

PMX-229 - Drug Profile 119

PMX-247 - Drug Profile 120

PMX-633 - Drug Profile 121

PMX-668 - Drug Profile 122

PMX-693 - Drug Profile 123

PMX-843 - Drug Profile 124

PP-0121 - Drug Profile 125

Proteins for Infectious Diseases - Drug Profile 127

PT-5 - Drug Profile 128

Recombinant Protein for Escherichia Coli Infections - Drug Profile 129

RX-05 - Drug Profile 130

RXP-873 - Drug Profile 131

SE-1 - Drug Profile 132

Shigetec - Drug Profile 133

SLP-0901 - Drug Profile 134

SLP-0905 - Drug Profile 135

Small Molecule for Malaria and Bacterial Infections - Drug Profile 136

Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile 137

Small Molecules for Bacterial Infections and Lung Infection - Drug Profile 138

Small Molecules for Escherichia Coli Infections - Drug Profile 139

Small Molecules for Escherichia coli Infections - Drug Profile 140

Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 141

Small Molecules to Inhibit 16S rRNA, Topoisomerases II and IV for Bacterial Infections - Drug Profile 142

Small Molecules to Inhibit Aminoacyl-tRNA Synthetases for Bacterial Infections - Drug Profile 143

Small Molecules to Inhibit RecA for Bacterial Infections - Drug Profile 144

SPR-741 - Drug Profile 145

Synthetic Peptide for Gram-Negative Bacterial Infections - Drug Profile 146

Synthetic Peptide for Oncology and Infectious Disease - Drug Profile 147

Synthetic Peptide to Antagonize TLR-4 for Oncology, Immunology and Infectious Disease - Drug Profile 148

Synthetic Peptide to Target Bacterial Cell Membrane for Gram Negative and Gram Positive Bacterial Infections - Drug Profile 149

Synthetic Peptides for Escherichia Coli Infections - Drug Profile 150

TP-6076 - Drug Profile 151

VAR-10100 - Drug Profile 152

Escherichia coli Infections - Dormant Projects 153

Escherichia coli Infections - Discontinued Products 156

Escherichia coli Infections - Product Development Milestones 157

Featured News & Press Releases 157

Appendix 159

Methodology 159

Coverage 159

Secondary Research 159

Primary Research 159

Expert Panel Validation 159

Contact Us 159

Disclaimer 160

List of Tables

List of Tables

Number of Products under Development for Escherichia coli Infections, H2 2016 15

Number of Products under Development for Escherichia coli Infections – Comparative Analysis, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Number of Products under Development by Companies, H2 2016 (Contd..1) 18

Number of Products under Investigation by Universities/Institutes, H2 2016 20

Comparative Analysis by Clinical Stage Development, H2 2016 21

Comparative Analysis by Early Stage Development, H2 2016 22

Products under Development by Companies, H2 2016 23

Products under Development by Companies, H2 2016 (Contd..1) 24

Products under Development by Companies, H2 2016 (Contd..2) 25

Products under Investigation by Universities/Institutes, H2 2016 26

Escherichia coli Infections – Pipeline by Adenium Biotech ApS, H2 2016 27

Escherichia coli Infections – Pipeline by Arsanis, Inc., H2 2016 28

Escherichia coli Infections – Pipeline by AstraZeneca Plc, H2 2016 29

Escherichia coli Infections – Pipeline by AvidBiotics Corp, H2 2016 30

Escherichia coli Infections – Pipeline by Cellceutix Corp, H2 2016 31

Escherichia coli Infections – Pipeline by Debiopharm International SA, H2 2016 32

Escherichia coli Infections – Pipeline by Emergent BioSolutions Inc, H2 2016 33

Escherichia coli Infections – Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 34

Escherichia coli Infections – Pipeline by GangaGen Inc, H2 2016 35

Escherichia coli Infections – Pipeline by Hsiri Therapeutics LLC, H2 2016 36

Escherichia coli Infections – Pipeline by Johnson & Johnson, H2 2016 37

Escherichia coli Infections – Pipeline by Melinta Therapeutics Inc, H2 2016 38

Escherichia coli Infections – Pipeline by Merck & Co Inc, H2 2016 39

Escherichia coli Infections – Pipeline by Microbiotix Inc, H2 2016 40

Escherichia coli Infections – Pipeline by Nabriva Therapeutics AG, H2 2016 41

Escherichia coli Infections – Pipeline by Navigen Pharmaceuticals, Inc., H2 2016 42

Escherichia coli Infections – Pipeline by Nosopharm SAS, H2 2016 43

Escherichia coli Infections – Pipeline by Novabiotics Ltd, H2 2016 44

Escherichia coli Infections – Pipeline by Omnia Molecular Ltd, H2 2016 45

Escherichia coli Infections – Pipeline by Paratek Pharmaceuticals Inc, H2 2016 46

Escherichia coli Infections – Pipeline by Pherecydes Pharma SA, H2 2016 47

Escherichia coli Infections – Pipeline by Phico Therapeutics Ltd, H2 2016 48

Escherichia coli Infections – Pipeline by Procarta Biosystems Limited, H2 2016 49

Escherichia coli Infections – Pipeline by Sealife PHARMA GMBH, H2 2016 50

Escherichia coli Infections – Pipeline by Sequoia Sciences Inc, H2 2016 51

Escherichia coli Infections – Pipeline by Soligenix Inc, H2 2016 52

Escherichia coli Infections – Pipeline by Syntiron LLC, H2 2016 53

Escherichia coli Infections – Pipeline by Tetraphase Pharmaceuticals Inc, H2 2016 54

Escherichia coli Infections – Pipeline by Varinel Inc, H2 2016 55

Assessment by Monotherapy Products, H2 2016 56

Number of Products by Stage and Target, H2 2016 58

Number of Products by Stage and Mechanism of Action, H2 2016 60

Number of Products by Stage and Route of Administration, H2 2016 62

Number of Products by Stage and Molecule Type, H2 2016 64

Escherichia coli Infections – Dormant Projects, H2 2016 158

Escherichia coli Infections – Dormant Projects (Contd..1), H2 2016 159

Escherichia coli Infections – Dormant Projects (Contd..2), H2 2016 160

Escherichia coli Infections – Discontinued Products, H2 2016 161

List of Figures

List of Figures

Number of Products under Development for Escherichia coli Infections, H2 2016 15

Number of Products under Development for Escherichia coli Infections – Comparative Analysis, H2 2016 16

Number of Products under Development by Companies, H2 2016 17

Number of Products under Investigation by Universities/Institutes, H2 2016 19

Comparative Analysis by Clinical Stage Development, H2 2016 21

Comparative Analysis by Early Stage Products, H2 2016 22

Assessment by Monotherapy Products, H2 2016 56

Number of Products by Top 10 Targets, H2 2016 57

Number of Products by Stage and Top 10 Targets, H2 2016 57

Number of Products by Top 10 Mechanism of Actions, H2 2016 59

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 59

Number of Products by Routes of Administration, H2 2016 61

Number of Products by Stage and Routes of Administration, H2 2016 61

Number of Products by Top 10 Molecule Types, H2 2016 63

Number of Products by Stage and Top 10 Molecule Types, H2 2016 63

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports